BR112014003886A2 - composto; uso de um composto; composição farmacêutica para inibir seletivamente amida hidrolase de ácido graxo (faah) periférica; composição farmacêutica para tratamento de uma condição selecionada de dor, inflamação e um distúrbio imune; método de tratar dor e/ou inflamação; método para tratar uma condição selecionada do grupo consistindo em dor, inflamação e um distúrbio imune; método para aumentar em um mamífero em necessidade dos mesmos níveis periféricos de anandamida, oleoiletanolamida (oea), palmitiletanolamida (pea) ou estearoiletanolamida (sea); composição farmacêutica e método para tratar uma condição selecionada de dermatite, mucosite ou a superreatividade de neurônios sensoriais periféricos, neurodermatite, bexiga superaperativa ou tosse - Google Patents
composto; uso de um composto; composição farmacêutica para inibir seletivamente amida hidrolase de ácido graxo (faah) periférica; composição farmacêutica para tratamento de uma condição selecionada de dor, inflamação e um distúrbio imune; método de tratar dor e/ou inflamação; método para tratar uma condição selecionada do grupo consistindo em dor, inflamação e um distúrbio imune; método para aumentar em um mamífero em necessidade dos mesmos níveis periféricos de anandamida, oleoiletanolamida (oea), palmitiletanolamida (pea) ou estearoiletanolamida (sea); composição farmacêutica e método para tratar uma condição selecionada de dermatite, mucosite ou a superreatividade de neurônios sensoriais periféricos, neurodermatite, bexiga superaperativa ou tosseInfo
- Publication number
- BR112014003886A2 BR112014003886A2 BR112014003886A BR112014003886A BR112014003886A2 BR 112014003886 A2 BR112014003886 A2 BR 112014003886A2 BR 112014003886 A BR112014003886 A BR 112014003886A BR 112014003886 A BR112014003886 A BR 112014003886A BR 112014003886 A2 BR112014003886 A2 BR 112014003886A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- inflammation
- pain
- pharmaceutical composition
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525636P | 2011-08-19 | 2011-08-19 | |
| US61/525,636 | 2011-08-19 | ||
| PCT/US2012/051478 WO2013028570A2 (en) | 2011-08-19 | 2012-08-17 | Meta-substituted biphenyl peripherally restricted faah inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112014003886A2 true BR112014003886A2 (pt) | 2017-03-21 |
| BR112014003886A8 BR112014003886A8 (pt) | 2018-01-23 |
| BR112014003886B1 BR112014003886B1 (pt) | 2022-04-19 |
Family
ID=47747054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014003886-4A BR112014003886B1 (pt) | 2011-08-19 | 2012-08-17 | Composto, composição farmacêutica, e, uso de um composto |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9745255B2 (pt) |
| EP (1) | EP2744778B1 (pt) |
| JP (1) | JP6092870B2 (pt) |
| KR (1) | KR102079404B1 (pt) |
| CN (1) | CN104203906B (pt) |
| AU (1) | AU2012299060B2 (pt) |
| BR (1) | BR112014003886B1 (pt) |
| CA (1) | CA2844812C (pt) |
| DK (1) | DK2744778T3 (pt) |
| ES (1) | ES2708723T3 (pt) |
| HK (1) | HK1198644A1 (pt) |
| MX (1) | MX354772B (pt) |
| WO (1) | WO2013028570A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100485727B1 (ko) * | 2004-06-24 | 2005-04-27 | 주식회사 바이오리더스 | 폴리감마글루탐산-비타민 복합체 및 그 용도 |
| ES2708723T3 (es) | 2011-08-19 | 2019-04-10 | Univ California | Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo |
| WO2014023325A1 (en) * | 2012-08-06 | 2014-02-13 | Fondazione Istituto Italiano Di Tecnologia | Multitarget faah and cox inhibitors and therapeutical uses thereof |
| WO2015157313A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
| RU2737893C2 (ru) | 2015-08-11 | 2020-12-04 | Айсью Медсинз Б.В. | Пэгилированная липидная наночастица с биоактивным липофильным соединением |
| US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| SG10201807034XA (en) | 2017-09-05 | 2019-04-29 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease |
| BR112021013515A2 (pt) * | 2019-01-10 | 2021-09-14 | Travecta Therapeutics Pte. Ltd. | Compostos de anandamida |
| WO2022020756A1 (en) * | 2020-07-23 | 2022-01-27 | John Mansell | Compositions and methods for treating pain and anxiety disorders |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4325889A (en) | 1978-08-04 | 1982-04-20 | Bayer Aktiengesellschaft | Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid) |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| US5559410A (en) | 1992-12-17 | 1996-09-24 | Valeo Systemes D'essuyage | Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield |
| US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
| US6271015B1 (en) | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
| CA2206192A1 (en) | 1996-06-13 | 1997-12-13 | F. Hoffmann-La Roche Ag | Modulation of lc132 (opioid-like) receptor function |
| JP2001504852A (ja) | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 双極性障害の治療のためのｎｋ−１受容体拮抗薬の使用 |
| GB9701453D0 (en) | 1997-01-24 | 1997-03-12 | Leo Pharm Prod Ltd | Aminobenzophenones |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US6281243B1 (en) | 1998-02-26 | 2001-08-28 | Akzo Nobel N.V. | Derivatives of azetidine and pyrrolidine |
| US6348498B1 (en) | 1998-05-29 | 2002-02-19 | Neurosciences Research Foundation, Inc. | Control of pain with endogenous cannabinoids |
| US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US20030134894A1 (en) | 1999-04-07 | 2003-07-17 | Daniele Piomelli | Methods of treating mental diseases, inflammation and pain |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| EP1509489B1 (en) | 2002-05-16 | 2011-07-13 | Sunovion Pharmaceuticals Inc. | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| FR2842808B1 (fr) | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques |
| UA80841C2 (en) * | 2002-10-07 | 2007-11-12 | Univ California | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) |
| FR2850377B1 (fr) | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| US20070155707A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
| US9316633B2 (en) | 2006-11-16 | 2016-04-19 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| US20080119549A1 (en) * | 2006-11-20 | 2008-05-22 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| TW200948805A (en) | 2008-03-07 | 2009-12-01 | Sigma Tau Ind Farmaceuti | Enol carbamate derivatives as modulators of fatty acid amide hydrolase |
| EP2488486B1 (en) | 2009-10-13 | 2019-08-14 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
| US9187413B2 (en) | 2010-07-28 | 2015-11-17 | The Regents Of The University Of California | Peripherally restricted FAAH inhibitors |
| WO2012167133A2 (en) | 2011-06-01 | 2012-12-06 | The Regents Of The University Of California | Inhibitors of anandamide transport and their therapeutic uses |
| ES2708723T3 (es) | 2011-08-19 | 2019-04-10 | Univ California | Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo |
| WO2015157313A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
-
2012
- 2012-08-17 ES ES12826376T patent/ES2708723T3/es active Active
- 2012-08-17 CA CA2844812A patent/CA2844812C/en active Active
- 2012-08-17 DK DK12826376.1T patent/DK2744778T3/en active
- 2012-08-17 AU AU2012299060A patent/AU2012299060B2/en active Active
- 2012-08-17 WO PCT/US2012/051478 patent/WO2013028570A2/en active Application Filing
- 2012-08-17 JP JP2014526261A patent/JP6092870B2/ja active Active
- 2012-08-17 CN CN201280051448.5A patent/CN104203906B/zh active Active
- 2012-08-17 EP EP12826376.1A patent/EP2744778B1/en active Active
- 2012-08-17 KR KR1020147007303A patent/KR102079404B1/ko active IP Right Grant
- 2012-08-17 MX MX2014001966A patent/MX354772B/es active IP Right Grant
- 2012-08-17 BR BR112014003886-4A patent/BR112014003886B1/pt active IP Right Grant
-
2014
- 2014-02-18 US US14/183,073 patent/US9745255B2/en active Active
- 2014-12-01 HK HK14112102.4A patent/HK1198644A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX354772B (es) | 2018-03-21 |
| BR112014003886B1 (pt) | 2022-04-19 |
| ES2708723T3 (es) | 2019-04-10 |
| KR20150100485A (ko) | 2015-09-02 |
| JP6092870B2 (ja) | 2017-03-08 |
| AU2012299060B2 (en) | 2017-06-01 |
| CN104203906B (zh) | 2018-03-13 |
| HK1198644A1 (en) | 2015-05-22 |
| WO2013028570A2 (en) | 2013-02-28 |
| US20140288170A1 (en) | 2014-09-25 |
| DK2744778T3 (en) | 2019-03-04 |
| JP2014527532A (ja) | 2014-10-16 |
| BR112014003886A8 (pt) | 2018-01-23 |
| AU2012299060A1 (en) | 2014-04-03 |
| US9745255B2 (en) | 2017-08-29 |
| EP2744778A2 (en) | 2014-06-25 |
| NZ622480A (en) | 2016-05-27 |
| CA2844812C (en) | 2019-10-22 |
| EP2744778A4 (en) | 2015-04-08 |
| CN104203906A (zh) | 2014-12-10 |
| KR102079404B1 (ko) | 2020-02-19 |
| EP2744778B1 (en) | 2019-01-16 |
| CA2844812A1 (en) | 2013-02-28 |
| WO2013028570A3 (en) | 2013-04-18 |
| MX2014001966A (es) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014003886A8 (pt) | composto; uso de um composto; composição farmacêutica para inibir seletivamente amida hidrolase de ácido graxo (faah) periférica; composição farmacêutica para tratamento de uma condição selecionada de dor, inflamação e um distúrbio imune; método de tratar dor e/ou inflamação; método para tratar uma condição selecionada do grupo consistindo em dor, inflamação e um distúrbio imune; método para aumentar em um mamífero em necessidade dos mesmos níveis periféricos de anandamida, oleoiletanolamida (oea), palmitiletanolamida (pea) ou estearoiletanolamida (sea); composição farmacêutica e método para tratar uma condição selecionada de dermatite, mucosite ou a superreatividade de neurônios sensoriais periféricos, neurodermatite, bexiga superaperativa ou tosse | |
| WO2008070001A3 (en) | Transcranial magnetic stimulation (tms) methods and apparatus | |
| DK2862353T3 (da) | Fremgangsmåde og apparat til effektiv skivehovedbehandling | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| BR112013012868A2 (pt) | processo e aparelho para purificar material de talol, e, usos de um aparelho, de hidrocarbonetos, e de ácidos graxos, ácidos de resina e substâncias neutras | |
| EA201291031A1 (ru) | Способ лечения ожирения с применением антиоксидантных модуляторов воспаления | |
| DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
| BR112016026556A2 (pt) | inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção | |
| BR112013024169A2 (pt) | método para o tratamento e prevenção da doença de parkinson | |
| BRPI0923164A2 (pt) | formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica. | |
| BR112012029041A2 (pt) | ''método de extração para remoção de substâncias flavorizantes indesejadas dispositivo e distribuição de cervejaria com um dispositivo de extração'' | |
| FR2986413B1 (fr) | Dispositif implantable du type interface neuronale et procede associe | |
| HK1206665A1 (en) | Method and apparatus for the treatment of spasmodic dysphonia | |
| FI20116085L (fi) | Menetelmä ja laite aivojen transkraniaalisen stimulaation vaikutusten määrittämiseksi | |
| BR112012002001A2 (pt) | método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit | |
| FR2990348B1 (fr) | Composition et procede de soin cosmetique utilisant un melange elastique | |
| BR112013001417A2 (pt) | dispositivo para o teste de um indivíduo para a detecção de um estado de uma patologia vascular do indivíduo e método para o teste de um indivíduo para a detecção de um estado de uma patologia vascular do indivíduo | |
| BRPI0911098A2 (pt) | formulação lipossomal e método para tratamento de bexiga hiperativa. | |
| ECSP15002095A (es) | Formulación farmacéutica | |
| CL2014003524A1 (es) | Aparato y método para tratamiento de aguas residuales biologicas | |
| FR3041449B1 (fr) | Procede et dispositif d'amelioration de la securite de plateforme maritime | |
| FR2976500B1 (fr) | Procede et dispositif de sepation chromatographique a contre-courant simule a faible perte de charge et nombre de zones eleve. | |
| HUE042625T2 (hu) | Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban | |
| WO2016134257A8 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | |
| HK1205932A1 (en) | Pharmaceutical formulation for bedwetting and method of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B152 | Others concerning applications: decision cancelled [chapter 15.32 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2012, OBSERVADAS AS CONDICOES LEGAIS. |